Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia
Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 8; DOI: 10.1186/s40425-018-0316-z